Ahmet Gursoy, MD
Clinical Cardiac Electrophysiology · Naples, FLNPI 1174516546
Payments from drug & device makers
Across 345 payments — averaging $21.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lundbeck LLC$2K
- Johnson & Johnson$1K
- Novo Nordisk$568
- Novartis$567
- Boehringer Ingelheim$450
- Merck$391
- plus $2K from 21 others
What the payments were for
- Consulting fees$2,00027%
- Food & beverage$5,45073%
- Education$140%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lundbeck LLC | 7 | $2,126 |
| Johnson & Johnson | 142 | $1,363 |
| Novo Nordisk | 32 | $568 |
| Novartis | 30 | $567 |
| Boehringer Ingelheim | 22 | $450 |
| Merck | 18 | $391 |
| Medtronic(2 entities) | 12 | $330 |
| Amgen | 17 | $321 |
| Scpharmaceuticals Inc. | 14 | $311 |
| Alnylam Pharmaceuticals Inc. | 12 | $283 |
| Lexicon Pharmaceuticals, Inc. | 6 | $107 |
| Abbott | 5 | $103 |
| Preventice Services, LLC | 3 | $89 |
| AstraZeneca | 5 | $75 |
| Esperion Therapeutics, Inc. | 4 | $62 |
| Bayer | 2 | $51 |
| Amarin Pharma, Inc. | 2 | $42 |
| Pfizer | 2 | $34 |
| Bridgebio Pharma, Inc. | 1 | $31 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $27 |
| Braemar Manufacturing, LLC | 1 | $24 |
| Biosense Webster, Inc. | 1 | $24 |
| GSK | 1 | $22 |
| Sanofi-aventis U.S. LLC | 1 | $20 |
| Lilly USA, LLC | 1 | $15 |
| Galderma Laboratories, L.p. | 1 | $15 |
| Boston Scientific | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NORTHERA$2,000
How this compares
$7,464 in reported general payments places this provider in the 10th percentile of 249 clinical cardiac electrophysiology providers in Florida.
See all clinical cardiac electrophysiology providers in Florida →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyndamaxTafamidis | 31 | $836,044 |
| EntrestoSacubitril/Valsartan | 329 | $452,563 |
| XareltoRivaroxaban | 410 | $426,332 |
| EliquisApixaban | 277 | $357,097 |
| JardianceEmpagliflozin | 184 | $218,375 |
| NortheraDroxidopa | 18 | $197,801 |
| OzempicSemaglutide | 104 | $100,994 |
| Propafenone Hcl ErPropafenone Hcl | 191 | $46,119 |
| Repatha SureclickEvolocumab | 46 | $40,451 |
| FarxigaDapagliflozin Propanediol | 15 | $22,520 |
| CorlanorIvabradine Hcl | 20 | $17,692 |
| Praluent PenAlirocumab | 33 | $16,086 |
| VerquvoVericiguat | 20 | $15,463 |
| Flecainide Acetate | 261 | $13,871 |
| VascepaIcosapent Ethyl | 12 | $11,576 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerVyndamax, Eliquis | $34 | $1,193,141308 claims |
| NovartisEntresto | $567 | $452,563329 claims |
| Johnson & JohnsonXarelto | $1,363 | $426,332410 claims |
| Boehringer IngelheimJardiance | $450 | $218,375184 claims |
| Lundbeck LLCNorthera | $2,126 | $197,80118 claims |
| Novo NordiskOzempic | $568 | $100,994104 claims |
| AstraZenecaFarxiga | $75 | $22,52015 claims |
| AmgenCorlanor | $321 | $17,69220 claims |
| MerckVerquvo | $391 | $15,46320 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 10th percentile of 249 clinical cardiac electrophysiology providers in Florida.
Other clinical cardiac electrophysiology in Naples
- Dinesh SharmaNaples$665K
- Kenneth PlunkittNaples$282K
- Jose Osorio FilhoMiami$16.4M
- Saumil OzaJacksonville$4.1M
- Usman SiddiquiWinter Park$3.6M
- David KenigsbergFort Lauderdale$1.3M
- Venkata SagiJacksonville$1.2M
- Raul WeissMiami Beach$1.1M
- Robert FishelAtlantis$1.1M
- Naushad ShaikKissimmee$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.